A Study of Iron Oligosaccharide in Chronic Kidney Disease Patients

Inclusion Criteria: Chronic kidney disease patients in pre-dialysis or undergoing dialysis not currently treated with parenteral iron may be included if they meet the following criteria: * ≥ 18 years of age at screening * Hb \< 110 g/L (6.8 mmol/L) * Serum ferritin \< 800 µgram/L * Life expectancy beyond 12 months * Willingness to participate after written informed consent Chronic kidney disease patients in pre-dialysis or undergoing dialysis willing to switch their current parenteral iron maintenance therapy to iron oligosaccharide may be included if they meet the following criteria: * ≥ 18 years of age at screening * Hb ≤ 130 g/L * Serum ferritin \> 200 µgram/L but \< 800 µgram/L * Life expectancy beyond 12 months * Willingness to participate after written informed consent Exclusion Criteria: * Non iron deficiency anaemia * Iron overload or disturbances in utilisation of iron (e.g. haemochromatosis, haemosiderosis) * Drug hypersensitivity (i.e. previous hypersensitivity to iron dextran or iron mono- or disaccharide complexes) * Patients with a history of multiple allergies. * Decompensated liver cirrhosis and hepatitis (alanine aminotransferase \> 3 times normal). * Acute or chronic infections * Rheumatoid arthritis with symptoms or signs of active inflammation * Pregnancy and nursing. To avoid pregnancy, women have to be postmenopausal, surgically sterile, sexually inactive or practice reliable contraception * Active bleeding * Planned elective surgery during the study where significant blood loss is expected * Participation in any other clinical trial within three months prior to screening